Search - tctmd.com

Displaying 261 - 275 of 275

Sort: Relevancy | Date

News Daily News

Ticagrelor Hits Mark in Large Stroke Study: THALES Top-line Results

Michael O'Riordan

January 27, 2020

News Daily News

Most Clinical Trial Sponsors Fail to Report Data as Mandated by FDA

Michael O'Riordan

January 21, 2020

News Daily News

Pot Talk: Review Urges Cardiologists to Discuss Marijuana Use

L.A. McKeown

January 21, 2020

News Daily News

Clopidogrel Interaction With Morphine in ACS Linked to More Ischemic Events

Shelley Wood

January 20, 2020

News Daily News

Injectable GLP-1 Agonist Semaglutide Gets CVD Event Reduction Indication

Michael O'Riordan

January 17, 2020

News Daily News

Hypertension Starts Years Earlier in Women Than Men, Serial BP Shows

L.A. McKeown

January 17, 2020

News Daily News

No Fewer MACE With Ticagrelor vs Clopidogrel in ACS Patients After PCI: Registry

Todd Neale

January 15, 2020

News Daily News

Lp(a) Reduction Contributes to Alirocumab’s Treatment Benefit: ODYSSEY Outcomes

Michael O'Riordan

January 14, 2020

News Daily News

Heart Failure Itself, Not Just the Hospital Stay, May Raise Long-term VTE Risk

Caitlin E. Cox

January 14, 2020

News Features

The Cancer Patient Needing PCI Poses Conundrums for Care

Shelley Wood

January 14, 2020

News Features

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

Michael O'Riordan

January 10, 2020

News Daily News

Most Secondary Prevention Patients Are Eligible for Multiple Drugs

Michael O'Riordan

January 03, 2020

News Opinion Conversations in Cardiology

Conversations in Cardiology: In the ISCHEMIA Era, What Role for FFR?

January 02, 2020

CME

Optimizing the Duration of DAPT following PCI

CME

Advertisement

Ticagrelor Hits Mark in Large Stroke Study: THALES Top-line Results

Most Clinical Trial Sponsors Fail to Report Data as Mandated by FDA

Pot Talk: Review Urges Cardiologists to Discuss Marijuana Use

Clopidogrel Interaction With Morphine in ACS Linked to More Ischemic Events

Injectable GLP-1 Agonist Semaglutide Gets CVD Event Reduction Indication

Hypertension Starts Years Earlier in Women Than Men, Serial BP Shows

No Fewer MACE With Ticagrelor vs Clopidogrel in ACS Patients After PCI: Registry

Lp(a) Reduction Contributes to Alirocumab’s Treatment Benefit: ODYSSEY Outcomes

Heart Failure Itself, Not Just the Hospital Stay, May Raise Long-term VTE Risk

The Cancer Patient Needing PCI Poses Conundrums for Care

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

Most Secondary Prevention Patients Are Eligible for Multiple Drugs

Conversations in Cardiology: In the ISCHEMIA Era, What Role for FFR?

Optimizing the Duration of DAPT following PCI

Aspirin for the Interventionalist: More Than Meets the Eye

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content